HSP110 improves the anti-tumor effects of the cytotoxic T lymphocyte epitope E749-57 in mice: HSP110 as a peptide specific chaperone or adjuvant?
Director, Translational and Correlative Studies Laboratory Abramson Family Cancer Research Institute University of Pennsylvania School of Medicine 422 Curie Boulevard Stellar-Chance Laboratories, room 409C Philadelphia, PA, 19104.
Michael
M
Kalos
D000276:Adjuvants, Immunologic; D000818:Animals; D000956:Antigens, Viral / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D000939:Epitopes / Q000276:immunology*; D005260:Female; D050957:HSP110 Heat-Shock Proteins / Q000276:immunology*; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D050725:Papillomavirus E7 Proteins / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D019496:Cancer Vaccines; D000939:Epitopes; D050957:HSP110 Heat-Shock Proteins; D050725:Papillomavirus E7 Proteins; D014765:Viral Vaccines